NCT07491822 2026-03-24
A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase NA Not yet recruiting